UNITY Biotechnology Inc KOL Call Transcript
Good morning and welcome to the Unity Biotechnology UBX1325 update call. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the Unity website following the conclusion of the event. I'd now like to turn the call over to Lynne Sullivan, Chief Financial Officer of Unity Biotechnology. Please go ahead, Lynne.
Thanks. Good morning, and thank you for joining Unity Biotechnology's conference call to review additional data from the Phase 2 BEHOLD study of UBX1325 in patients with DME. We will also provide an update on our ongoing Phase 2 ENVISION study, which has data reading out at the end of Q1.
With me today on today's call is Anirvan Ghosh, the CEO of Unity Biotechnology; Jamie Dananberg, our Chief Medical Officer; and myself, Lynne Sullivan, the Chief Financial Officer. Unfortunately, Dr. Bhisitkul is unable to join us this morning as he fractured his elbow skiing this weekend.
Before turning the call over to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |